Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Diagnosis of RSV in Birth Cohort and Phase 2a Trial of JNJ-53718678 in Infants With Acute Respiratory Tract Infection Due to RSV
2019-001509-25Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Part 1 primary endpoints. Status: unknown.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-001509-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001509-25.